Quantcast

Latest Cambridge Antibody Technology Stories

2011-08-15 08:06:00

NEW YORK, Aug. 15, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell based therapeutics development, today reported on important progress toward the commencement of a Phase II clinical trial for AMR-001, the lead product candidate of Amorcyte, Inc. ("Amorcyte") for the treatment of acute myocardial infarction. This comes after recent positive developments with respect to moving AMR-001 through...

2011-07-13 04:00:00

GENEVA, July 13, 2011 /PRNewswire/ -- Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today the Company's CEO, Dr. Igor Fisch, has been elected to Affitech's (NASDAQ OMX Copenhagen) board of directors effective April 28, 2011. Denmark-based Affitech is a biotechnology company dedicated to the discovery and development of human antibody based therapeutics in cancer and...

2011-05-10 08:00:00

SAN DIEGO, May 10, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology(TM) platform, announced today a three year strategic collaboration with MedImmune LLC, the global biologics business of AstraZeneca. The agreement provides MedImmune with non-exclusive access to Pfenex Expression Technology and scientific resources for the development of bioprocesses for human therapeutic proteins and vaccines. Pfenex Inc. will engineer...

2011-03-16 04:11:00

SHANGHAI, March 16, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment....

2011-03-11 04:00:00

BURLINGAME, Calif., March 11, 2011 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, announced today that its partner, Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) of China to evaluate APX003 (also known as BD0801) as a potential cancer therapy. APX003 is a...

2011-03-10 14:23:13

The long path to Benlysta emphasizes importance of basic research Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues. "I am deeply gratified that our scientific...

2011-01-07 09:28:00

GAITHERSBURG, Md., Jan. 7, 2011 /PRNewswire/ -- MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases. Under the terms of the agreement, Amgen grants MedImmune rights to develop AMG...

2011-01-06 15:09:00

THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(®)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases. Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a...

2010-12-07 04:00:00

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs. Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and...

2010-11-22 04:30:00

THOUSAND OAKS, Calif., Nov 22, 2010 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that it has received a $244,479 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to the development of ImmunGene's technology which is based on antibody-cytokine fusions that have demonstrated targeted toxicity...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.